Nalaganje...
Multiple sclerosis, rituximab, and COVID‐19
We conducted a retrospective cohort study in Kaiser Permanente Southern California from 1 January 2020 to 30 September 2020. We found that rituximab‐treated persons with multiple sclerosis (pwMS, n = 1895) were more likely be hospitalized (n = 8, 33.3%), but not die (n = 0) from COVID‐19, compared t...
Shranjeno v:
| izdano v: | Ann Clin Transl Neurol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8045943/ https://ncbi.nlm.nih.gov/pubmed/33783140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.51342 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|